Chlamydia screening for pregnant women aged 16-25 years attending an antenatal service: a cost-effectiveness study


Autoria(s): Ong, J.J.; Chen, M.; Hocking, J.; Fairley, C.K.; Carter, R.; Bulfone, L.; Hsueh, A.
Data(s)

26/08/2015

Resumo

OBJECTIVE: Determine the cost-effectiveness of screening all pregnant women aged 16-25 years for chlamydia compared with selective screening or no screening. DESIGN: Cost effectiveness based on a decision model. SETTING: Antenatal clinics in Australia. SAMPLE: Pregnant women, aged 16-25 years. METHODS: Using clinical data from a previous study, and outcomes data from the literature, we modelled the short-term perinatal (12-month time horizon) incremental direct costs and outcomes from a government (as the primary third-party funder) perspective for chlamydia screening. Costs were derived from the Medicare Benefits Schedule, Pharmaceutical Benefits Scheme, and average cost-weights reported for hospitalisations classified according to the Australian refined diagnosis-related groups. MAIN OUTCOME MEASURES: Direct costs of screening and managing chlamydia complications, number of chlamydia cases detected and treated, and the incremental cost-effectiveness ratios were estimated and subjected to sensitivity analyses. RESULTS: Assuming a chlamydia prevalence rate of 3%, screening all antenatal women aged 16-25 years at their first antenatal visit compared with no screening was $34,931 per quality-adjusted life-years gained. Screening all women could result in cost savings when chlamydia prevalence was higher than 11%. The incremental cost-effectiveness ratios were most sensitive to the assumed prevalence of chlamydia, the probability of pelvic inflammatory disease, the utility weight of a positive chlamydia test and the cost of the chlamydia test and doctor's appointment. CONCLUSION: From an Australian government perspective, chlamydia screening of all women aged 16-25 years old during one antenatal visit was likely to be cost-effective compared with no screening or selective screening, especially with increasing chlamydia prevalence. TWEETABLE ABSTRACT: Chlamydia screening for all pregnant women aged 16-25 years during an antenatal visit is cost effective.

Identificador

http://hdl.handle.net/10536/DRO/DU:30078355

Idioma(s)

eng

Publicador

Wiley

Relação

http://dro.deakin.edu.au/eserv/DU:30078355/carter-chlamydiascreening-2015.pdf

http://www.dx.doi.org/10.1111/1471-0528.13567

http://www.ncbi.nlm.nih.gov/pubmed/26307516

Direitos

2015, Wiley

Palavras-Chave #Antenatal #chlamydia #cost-effectiveness #screening
Tipo

Journal Article